Eledoisin acetate salt structure
|
Common Name | Eledoisin acetate salt | ||
|---|---|---|---|---|
| CAS Number | 69-25-0 | Molecular Weight | 1188.396 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 1618.1±65.0 °C at 760 mmHg | |
| Molecular Formula | C54H85N13O15S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 932.4±34.3 °C | |
Use of Eledoisin acetate saltEledoisin is a specific agonist of NK2 and NK3 receptors. Sequence: {Glp}-Pro-Ser-Lys-Asp-Ala-Phe-Ile-Gly-Leu-Met-NH2. |
| Name | Eledoisin |
|---|---|
| Synonym | More Synonyms |
| Description | Eledoisin is a specific agonist of NK2 and NK3 receptors. Sequence: {Glp}-Pro-Ser-Lys-Asp-Ala-Phe-Ile-Gly-Leu-Met-NH2. |
|---|---|
| Related Catalog | |
| Target |
NK2 and NK3 receptors[1]. |
| In Vitro | Eledoisin increases the value recorded under basal conditions by 24.5±3.7%; this stimulation is significantly (P<0.01) lowered to 13.1±1.9% by the simultaneous presence of CP99994. The same protocol is also used to characterize the sensitivity of Eledoisin stimulation to 0.1 μM SR48968 or 0.1 μM SB222200. SR48968 significantly (P < 0.01) lower the stimulation by Eledoisin, while SB222200 has no effect. Eledoisin stimulation is reduced by CP99994 and SR48968, NK1 and NK2 antagonists, respectively[1]. |
| In Vivo | Eledoisin (0.1-1 nmol/kg) injected into rats produces a biphasic cardiovascular response that consists of an initial fall of systemic blood pressure (8-15 mm Hg) followed by a rise (20-22 mm Hg). Intracerebroventricular injection of Eledoisin produces an enhancement of grooming and scratching behavior in mice[2]. |
| References |
[2]. Severini C, et al. The tachykinin peptide family. Pharmacol Rev. 2002 Jun;54(2):285-322. |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 1618.1±65.0 °C at 760 mmHg |
| Molecular Formula | C54H85N13O15S |
| Molecular Weight | 1188.396 |
| Flash Point | 932.4±34.3 °C |
| Exact Mass | 1187.600830 |
| PSA | 463.25000 |
| LogP | -1.36 |
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
| Index of Refraction | 1.569 |
| Storage condition | −20°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| WGK Germany | 3 |
|---|---|
| RTECS | JX8688000 |
| 5-Oxo-L-prolyl-L-prolyl-L-seryl-L-lysyl-L-α-aspartyl-L-alanyl-L-phenylalanyl-L-isoleucylglycyl-L-leucyl-L-methioninamide |
| PGLU-PRO-SER-LYS-ASP-ALA-PHE-ILE-GLY-LEU-MET-NH2 |
| ELEDOSIN |
| GLP-PRO-SER-LYS-ASP-ALA-PHE-ILE-GLY-LEU-MET-NH2 |
| PYR-PRO-SER-LYS-ASP-ALA-PHE-ILE-GLY-LEU-MET-NH2 |
| eledonepeptide |
| 5-Oxo-L-prolyl-L-prolyl-L-seryl-L-lysyl-L-aspartyl-L-alanyl-L-phenylalanyl-L-isoleucylglycyl-L-leucyl-L-methioninamide |
| Eledone peptide |
| L-methioninamide, 5-oxo-L-prolyl-L-prolyl-L-seryl-L-lysyl-L-α-aspartyl-L-alanyl-L-phenylalanyl-L-isoleucylglycyl-L-leucyl- |
| pEPSKDAFIGLM-NH2 |
| FI 6225 TF/Ocoa |
| 5-Oxo-L-Pro-L-Pro-L-Ser-L-Lys-L-Asp-L-Ala-L-Phe-L-Ile-Gly-L-Leu-L-Met-NH2 |
| PYR-PSKDAFIGLM-NH2 |
| eledoisin |
| Eledoisin Acetate |